The FDA approval of dupilumab represents a major step forward for adults living with bullous pemphigoid (BP), one that is likely to transform how we manage this chronic autoimmune blistering condition.
The FDA approval of dupilumab represents a major step forward for adults living with bullous pemphigoid (BP), one that is likely to transform how we manage this chronic autoimmune blistering condition.
Dupilumab, a monoclonal antibody that blocks IL-4Rα and inhibits IL-4 and IL-13 signalling, is the first targeted therapy approved for bullous pemphigoid. It provides a much needed steroid sparing option with the potential to achieve sustained remission, relieve itch, and reduce treatment related toxicity, which is particularly important in this often older and vulnerable patient population.
The approval is based on data from the pivotal LIBERTY-BP ADEPT (NCT04206553) phase 2/3 trial, which evaluated the efficacy and safety of dupilumab compared with placebo in adults with moderate to severe bullous pemphigoid.
To explore the significance of this development, the key data that led to approval, and how dupilumab may be integrated into real world clinical practice, along with practical considerations for clinicians when initiating treatment, we spoke with Prof. Dedee Murrell, a leading expert in the field and a principal investigator of the LIBERTY-BP ADEPT trial.
Questions
- What does the FDA approval of dupilumab mean for those living with bullous pemphigoid? (0:10)
- Aside from efficacy, what other clinical benefits did dupilumab show in the LIBERTY-BP ADEPT trial? (2:18)
- Where do you see dupilumab fitting into the treatment algorithm for bullous pemphigoid? (3:14)
- What practical considerations should clinicians keep in mind when starting dupilumab for bullous pemphigoid? (4:29)
Disclosures: This short article was prepared by touchDERMATOLOGY in collaboration with Prof. Murrell. No fees or funding were associated with its publication.
Prof. Dedee Murrell has served as a consultant for ArgenX, Janssen, Ono, Principia Biopharma, Roche and Regeneron Sanofi. She has received trial investigator fees from ArgenX, Janssen and Regeneron Sanofi. She has participated in advisory boards for Regeneron Sanofi, ArgenX, Principia Biopharma, Roche and Janssen, and has been a speaker for Regeneron Sanofi.
Further content in autoimmune diseases.
This content has been developed independently by Touch Medical Media. Unapproved products or unapproved uses of approved products may be discussed; these situations may reflect the approval status in one or more jurisdictions. No endorsement of unapproved products or unapproved uses is either made or implied by mention of these products or uses by Touch Medical Media. Views expressed are the speaker’s own and do not necessarily reflect the views of Touch Medical Media.
Register now to receive the touchDERMATOLOGY newsletter!
Don’t miss out on hearing about our latest articles, expert opinions, conference news, podcasts and more.
Cite: Murrell D. How dupilumab is set to transform bullous pemphigoid treatment. TouchDERMATOLOGY. 29 July 2025.
